ConductScience.org, home
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
API referenceFor AI assistants

Trial · NCT03334435

Participant flow150

How many started, completed or left each group, period by period.

1 to 20 of 150

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Treatment Period 1: Week 0 to Week 52STARTEDPlacebo91
Treatment Period 1: Week 0 to Week 52STARTEDBaricitinib (Bari) 1- Milligram (mg)45
Treatment Period 1: Week 0 to Week 52STARTEDBari 2-mg519
Treatment Period 1: Week 0 to Week 52STARTEDBari 4-mg743
Treatment Period 1: Week 0 to Week 52STARTEDBari 2-mg Open-Label Addendum247
Treatment Period 1: Week 0 to Week 52STARTED2 mg Bari to Placebo Substudy0
Treatment Period 1: Week 0 to Week 52STARTED2 mg Bari to 1 mg Bari Substudy0
Treatment Period 1: Week 0 to Week 52STARTED2 mg Bari to 2 mg Bari Substudy0
Treatment Period 1: Week 0 to Week 52STARTED4 mg Bari to Placebo Substudy0
Treatment Period 1: Week 0 to Week 52STARTED4 mg Bari to 2 mg Bari Substudy0
Treatment Period 1: Week 0 to Week 52STARTED4 mg Bari to 4 mg Bari Substudy0
Treatment Period 1: Week 0 to Week 52STARTEDPlacebo to Placebo Non-substudy0
Treatment Period 1: Week 0 to Week 52STARTED1 mg Bari to 1 mg Bari Non-substudy0
Treatment Period 1: Week 0 to Week 52STARTED2 mg Bari to 2 mg Bari Non-substudy0
Treatment Period 1: Week 0 to Week 52STARTED4 mg Bari to 4 mg Bari Non-substudy0
Treatment Period 1: Week 0 to Week 52Received at Least 1 Dose of Investigational Product (IP)Placebo91
Treatment Period 1: Week 0 to Week 52Received at Least 1 Dose of Investigational Product (IP)Baricitinib (Bari) 1- Milligram (mg)45
Treatment Period 1: Week 0 to Week 52Received at Least 1 Dose of Investigational Product (IP)Bari 2-mg519
Treatment Period 1: Week 0 to Week 52Received at Least 1 Dose of Investigational Product (IP)Bari 4-mg743
Treatment Period 1: Week 0 to Week 52Received at Least 1 Dose of Investigational Product (IP)Bari 2-mg Open-Label Addendum247

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03334435/flow

API referenceFor AI assistants